| Dr Timothy T Chang, MD | |
|
2500 Metrohealth Dr, Cleveland, OH 44109-1900 | |
| (216) 778-7800 | |
| Not Available |
| Full Name | Dr Timothy T Chang |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 21 Years |
| Location | 2500 Metrohealth Dr, Cleveland, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447372446 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 35.091459 (Ohio) | Secondary |
| 207ND0900X | Dermatology - Dermatopathology | 35.091459 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Metrohealth System | Cleveland, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Metrohealth System | 8628982949 | 1026 |
News Archive
USA Today on Monday examined the debate over whether patients with terminal illnesses should have expanded access to experimental medications - an issue currently under consideration in a lawsuit before the U.S. Court of Appeals for the District of Columbia.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).
Researchers at the University of Colorado Anschutz Medical Campus have found that intense light amplifies a specific gene that bolsters blood vessels and offers protection against heart attacks.
› Verified 4 days ago
| Entity Name | The Metrohealth System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053353896 PECOS PAC ID: 8628982949 Enrollment ID: O20031119000355 |
News Archive
USA Today on Monday examined the debate over whether patients with terminal illnesses should have expanded access to experimental medications - an issue currently under consideration in a lawsuit before the U.S. Court of Appeals for the District of Columbia.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).
Researchers at the University of Colorado Anschutz Medical Campus have found that intense light amplifies a specific gene that bolsters blood vessels and offers protection against heart attacks.
› Verified 4 days ago
| Entity Name | Warren Dermatology And Mohs Surgery, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033591813 PECOS PAC ID: 8628384070 Enrollment ID: O20150831000664 |
News Archive
USA Today on Monday examined the debate over whether patients with terminal illnesses should have expanded access to experimental medications - an issue currently under consideration in a lawsuit before the U.S. Court of Appeals for the District of Columbia.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).
Researchers at the University of Colorado Anschutz Medical Campus have found that intense light amplifies a specific gene that bolsters blood vessels and offers protection against heart attacks.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Timothy T Chang, MD 2500 Metrohealth Dr, Cleveland, OH 44109-1900 Ph: (216) 464-7770 | Dr Timothy T Chang, MD 2500 Metrohealth Dr, Cleveland, OH 44109-1900 Ph: (216) 778-7800 |
News Archive
USA Today on Monday examined the debate over whether patients with terminal illnesses should have expanded access to experimental medications - an issue currently under consideration in a lawsuit before the U.S. Court of Appeals for the District of Columbia.
Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received tentative approval from the U.S. Food and Drug Administration (FDA) under the President's Emergency Plan for AIDS Relief (PEPFAR) for its New Drug Application (NDA) for Efavirenz Tablets, 50 mg, 100 mg and 200 mg. These innovative pediatric dosages in tablet form were developed by Matrix for use in treating pediatric HIV/AIDS.
Acorda Therapeutics, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for AMPYRA™ (dalfampridine), an oral treatment to improve walking in patients with multiple sclerosis (MS).
Researchers at the University of Colorado Anschutz Medical Campus have found that intense light amplifies a specific gene that bolsters blood vessels and offers protection against heart attacks.
› Verified 4 days ago
Carol C Slover, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 | |
Wilma F Bergfeld, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Cleveland, OH 44195 Phone: 800-223-2273 | |
Antoine Amado De Olazaval, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Desk A61, Cleveland, OH 44195 Phone: 216-445-3643 Fax: 216-636-5151 | |
Katherine Camille Disano, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-5394 | |
Dr. John Scott Anthony, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, St40, Cleveland, OH 44195 Phone: 440-878-2500 | |
Dr. Christine Jaworsky, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2500 Metrohealth Dr, Cleveland, OH 44109 Phone: 216-778-7800 | |
Christine M Poblete-lopez, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9500 Euclid Ave, Desk A61, Cleveland, OH 44195 Phone: 216-444-3345 |